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Jeffrey A. Bogart, MD
In contrast to the guarded outlook for the majority of patients diagnosed with non-smallcell lung cancer (NSCLC), the prospect for a cure is excellent after anatomic resection
for pathologic stage I disease.1 Nevertheless, a substantial number of patients with
early-stage NSCLC suffer from cardiopulmonary disease and/or other medical comor-
bidities, rendering them unsuitable for lobectomy.2 Treatment philosophies vary widely
for the “medically inoperable” population. Although still frequently encountered in
clinical practice, a nihilistic approach is not justified because the majority of patients with
untreated stage I NSCLC die from lung cancer, not from comorbid illnesses. Moreover,
recent observations suggest poorer outcomes for the cohort of patients that do not receive
any therapy.3,4
Fractionated external-beam radiotherapy has been the most frequently employed
treatment option by far, with outcomes contingent on patient selection, tumor burden, and,
perhaps, radiotherapy dose.5,6 As the importance of this patient population has become
apparent, several alternatives have emerged, including (thorascopic) wedge resection with
or without permanent brachytherapy, heavy-particle therapy (proton and carbon ion),
stereotactic radiosurgery, and radiofrequency ablation.7–12 Particularly encouraging is the
development of prospective multi-institutional cooperative group trials specific to this
population. Most trials are in progress or have recently completed accrual. CALGB 9335,
which assessed video-assisted thorascopic wedge resection and postoperative radiotherapy
for high-risk patients with pathologic stage IA NSCLC, is unique in providing long-term
outcomes for patients with well-defined cardiopulmonary dysfunction.13 Five-year sur-
vival was 29% for the cohort of 31 patients. This is in stark contrast to the 50% survival
reported in retrospective single-institution studies and illustrates the need for carefully
conducted prospective research.14,15
The relative merit of radiotherapy versus (limited) surgery for elderly and high-risk
patients has long been debated, with selected retrospective series used to defend opposing
viewpoints.16,17 The mature results of ongoing prospective phase II studies should finally
shed some light on the issue, although the standard caveats apply regarding patient
selection and the use of pathologic versus clinical staging. In this issue of the Journal of
Thoracic Oncology, Graham et al.18 report a retrospective comparison of surgery and
radiotherapy in stage I NSCLC treated at different centers in Australia during the 1990s.
Median and 5-year survival were 67 months and 54% for the surgery cohort (n  68)
compared with 43 months and 30% for the radiotherapy cohort (n  39). On multivariate
analysis, the only significant factor was performance status, and cancer-specific 5-year
survival for surgery and radiotherapy were similar at 59 and 53%, respectively.
The authors attribute their encouraging results to modern radiotherapy techniques
and to having accelerated the course of radiotherapy such that treatment was completed in
5 weeks. Prospective dose-escalation trials from the University of Michigan and the
Radiation Therapy Oncology Group (RTOG) show that doses up to 102.9 Gy could be
given to limited target volumes with three-dimensional conformal radiotherapy.19–21
Median survival ranged from 21 to 27 months for early-stage medically inoperable
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NSCLC, but an approach of protracted radiotherapy for
NSCLC has been questioned because of concerns of tumor
repopulation leading to reduced efficacy.22 Accelerating the
time to complete radiotherapy yields higher predicted bio-
logic efficacy, and accelerated therapy (54 Gy in 12 days)
bested conventional radiotherapy (60 Gy in 6 weeks) in the
randomized phase III continuous hyperfractionated acceler-
ated radiotherapy (“CHART”) study conducted in the United
Kingdom.23 A subset of 169 patients with stage I/IIA NSCLC
were included, although only a fraction of patients with
early-stage disease (20%) had clinical T1N0 lesions. Four-
year survival was significantly improved with CHART (18
versus 12%) but is less encouraging than the current retro-
spective report. Additional retrospective studies have sug-
gested encouraging outcomes with accelerated radiotherapy,
and a recent prospective pilot trial from the CALGB demon-
strated that treatment with a nominal dose of 70 Gy could
safely be accelerated from 6 weeks to less than 3.5 weeks
using conformal radiotherapy in high-risk stage I NSCLC,
although efficacy and late toxic effects of therapy are not yet
available.24–27
Stereotactic body radiosurgery (SBRS) employs sophisti-
cated techniques including stereotactic localization to precisely
deliver large doses of radiotherapy in a markedly accelerated
time course and has recently emerged as a treatment option for
early-stage NSCLC. A phase I trial at Indiana University
demonstrated that a dose of 6000 to 7200 cGy given in three
fractions could be safely delivered to peripheral stage I
NSCLC, and excellent short-term local tumor control was
obtained.28 Preliminary results of a subsequent phase II study
from Indiana University (n  70) include median survival of
32.6 months, 1-year local control of 97.8%, 1-year survival of
79%, and grade 3 to 5 toxic effects in 13 patients.29 Given the
technical expertise and support necessary for safe implemen-
tation of a body radiosurgery program, caution should be
exercised in generalizing results obtained by experienced
investigators. The results of a recently completed multi-
institutional RTOG trial are awaited, and additional prospec-
tive studies are planned.30 Although long-term survival with
SBRS is similar to reports of other radiotherapy options for
high-risk patients, the ability to minimize the number of
treatment sessions is an obvious benefit for a population with
significant comorbid medical illness.
The provocative short-term local tumor control
achieved with SBRS has shifted the radiotherapy versus
surgery debate to encompass fit patients with stage I NSCLC
who are candidates for lobectomy. A large retrospective
report from Japan included a subset of 85 stage I NSCLC
patients judged to be operable.31 The 5-year survival was 77
and 68% in clinical stage IA and IB disease, respectively
(median follow-up of 32 months). Earlier this year, a joint
symposium between Japanese and U.S. investigators focused
on considerations of developing a prospective randomized
comparison of surgery and SBRS for operable stage I
NSCLC. Nevertheless, it would be prudent to methodically
and patiently gather appropriate data before embarking on a
large-scale randomized study of SBRS in a highly curable
population. Long-term assessment is needed to define the true
rate of local tumor control with SRS because this assessment
is frequently confounded by the development of treatment-
related atelectasis and fibrosis, and the late toxic effects of
SBRS remain to be defined. Generally agreed-upon metrics
used to predict pulmonary toxicity with conventional radio-
therapy (e.g., V20) are not likely relevant with SBRS.32 The
efficacy and tolerability of SBRS from studies of patients
with underlying pulmonary dysfunction may not directly
translate to a good-risk population that has a much longer
expectation for survival. That being said, the potential for
SBRS to offer a routine noninvasive option for selected
patients with operable NSCLC underscores the impact of
advances in radiotherapy technology in expanding the arsenal
of curative therapies for NSCLC.
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